GenPat77 expects to bring its first commercial drug to market in 2002. The world market for therapeutic treatments is estimated to be $6.9 billion (E7.5 billion).
3i Germany puts DM5m (E2.6m) into GenPat77 Pharmacogenetics
The company develops treatments that assist patients dependent on immune therapies.
If you do not receive this within five minutes, please try to sign in again. If the problem persists, please email: